According to a story from PR Newswire, The Autoimmune Registry, Inc. (ARI) has recently released its first ever autoimmune diseases list. This list includes a total of over 150 distinct…
Did you know that there are multiple forms of multiple sclerosis (MS)? The most common form of MS is relapsing-remitting, meaning patients go through symptomatic periods and periods of remission.…
A series of articles recently published in FierceBiotech describe a discovery by Ohio State and Michigan University scientists. The teams have discovered an immune cell that could be tapped to…
Researchers at the Mayo Clinic have collaborated with the international community to develop a potential way to test for spinocerebellar ataxia type 3 (SCA3), also called Machado-Joseph Disease. Additionally, they…
In early October, global biopharmaceutical company Bristol Myers Squibb announced the Canadian approval of ZEPOSIA (ozanimod) for patients with multiple sclerosis (MS). In particular, the drug is designed to…
In conditions like multiple sclerosis or neuromyelitis optica, disease progression is spurred by the destruction of myelin, the protective coating around nerve cells. However, new research suggests that N-acetylglucosamine, a…
A study reported in NewsWise evaluates retinoid-x receptor (RXR) agonists as a treatment for recurring and refractory multiple sclerosis (MS). This specific RXR agonist, bexarotene, was found to help remyelination,…
Last week, biotechnology company Anokion SA ("Anokion") announced the FDA's acceptance of an Investigational New Drug (IND) application. Anokion submitted the IND for ANK-700, a therapy for patients with…
Happy Friday! September is a packed with rare disease awareness, as we've been featuring all month long. We wanted to make sure to draw attention to Dystonia Awareness Month, which…
Knowing how to help treat your disease and being able to afford those needs are two different questions. As reported in Newswise, in a study from Harvey L. Neiman Health Policy Institute, researchers…
According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…
Within the last month, BrainStorm Cell Therapeutics Inc. announced the publication of pre-clinical data on the NurOwn system. NurOwn technology produces autologous, bone marrow-derived mesenchymal stem cells (MSCs) for…
Recently, IVX Health announced the opening of three new Tampa-based infusion centers to treat patients with chronic conditions. Currently, IVX Health, who describes themselves as "[providing] biologic injections and infusions…
by Caitlin Seida from In The Cloud Copy Those living with autoimmune disorders like uveitis and multiple sclerosis know all too well that the cells within our bodies meant to…
According to an article in Science Alert first published in the journal The Conversation, researchers at the University of Birmingham have shown that it is possible to prevent the…
Moebius Syndrome Moebius syndrome is a rare condition that causes an inability to move the eyes laterally and facial paralysis. A similar type of paralysis can also occur as a…
Happy Thursday! This edition of the Patient Worthy Editor's Choice is coming to you a little early this week. If you're reading from the United States, we hope you enjoy…
60% of all those diagnosed with multiple sclerosis (MS) also suffer from some form of sleep disorder. Fatigue is a more common symptom than even the well-known tingling and numbness…
You have a number of different cells throughout your body, all of which perform different functions or provide support. One extremely interesting type are astrocytes, star-shaped glial cells that…
Leszek Ignatowicz, a researcher from Georgia State University, recently received a 5 year, almost 2 million dollar grant from the NIH for his investigation into multiple sclerosis (MS). This project…
According to a story from Multiple Sclerosis News Today, the drug company Bristol-Myers Squibb recently announced that its drug ozanimod (marketed as Zeposia) is now available for public use in…
In a story from Multiple Sclerosis News Today, multiple sclerosis is known for its variability- one patient's experience may look nothing like a friend's with the same disease. For this…
The European Commission has recently granted approval to Bristol Myers Squibb (BMS) for their multiple sclerosis (MS) treatment, Zeposia. It has already been approved by the FDA in the US…
According to a story from Medical Xpress, an Italian study has found that people in urban areas are at a 29 percent greater risk of developing multiple sclerosis (MS). This…
According to MedScape, tumor necrosis factor (TNF) inhibitors present severe issues for patients with autoimmune disorders. In particular, patients exposed to TNF inhibitors may experience inflammation throughout their central nervous…
© Copyright Patient Worthy
